The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested comments for 60 days on market concentration and contracting practices among group purchasing organizations and drug wholesalers to understand their potential impact on pricing and generic drug shortages.

“For years Americans have faced acute shortages of critical drugs, from chemotherapy to antibiotics, endangering patients,” said FTC Chair Lina Khan. “Our inquiry requests information on the factors driving these shortages and scrutinizes the practices of opaque drug middlemen. We look forward to public input as we assess how enforcers and policymakers can best address chronic drug shortages and promote a resilient drug supply chain.”

Related News Articles

Headline
The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote…
Headline
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in…
Headline
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar…
Headline
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price…
Headline
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation…
Headline
A new study by Business Group on Health reveals that, amid increases in the percentage of health care dollars spent on pharmacy, 92% of employers are…